2seventy, Bristol Myers
On Friday, 2Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $4.93 which represents a slight increase of $0.17 or 3.57% from the prior close of $4.76. The stock opened at $4.83 and ...
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...
The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.
据了解，2seventy ...
欢迎关注凯莱英药闻近期，诺和诺德在基因编辑领域进一步加码；首先是在2024年6月，公司以最高4000万美元收购2seventy bio的A ...
(Reuters) - 2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback